-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from the International Agency for Research on Cancer (IARC) in 2018, the incidence of breast cancer in female cancers worldwide is 24.
2%, ranking first among female cancers, with 52.
9% occurring in developing countries
.
Accurate risk assessment is critical to the success of breast cancer screening programs
Breast cancer screening
The risk model based on artificial intelligence (AI) has been proven, and compared with the current risk model used in clinical practice, it has made significant progress
.
However, the responsible deployment of new artificial intelligence requires careful verification among different groups of people
The researchers collected screening mammograms and pathologically confirmed breast cancer results from different regions, and assessed the consistency index of Uno to Mirai to predict the risk of breast cancer within 1 to 5 years after mammography
.
The receiver operating curve of Mirai when selecting high-risk cohorts in some test sets
The receiver operating curve of Mirai when selecting high-risk cohorts in some test setsA total of 128,793 mammograms of 62,185 individuals from 7 locations around the world were collected, of which 3815 individuals were diagnosed with breast cancer in the next 5 years
.
The consistency indexes obtained by Mirai in the 7 hospitals were 0.
In summary, Mirai is a risk model based on mammography.
It has maintained high accuracy in various test sets in 7 hospitals in 5 countries around the world
.
This is the most extensive verification of breast cancer models based on artificial intelligence so far, indicating that this technology can broadly improve the diagnosis and treatment of breast cancer
Mirai is a risk model based on mammography.
Original source:
Adam Yala, et al.
Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model Leave a message here